米氮平治疗轻中度抑郁症临床疗效对照研究

Control Study on Clinical Effect of Mirtazapine in Treatment Depression.

目的探讨米氮平治疗轻中度抑郁症的疗效及安全性.方法采用开放性治疗,氯丙咪嗪对照的方法,将符合CCMD-3诊断标准的58例抑郁症随机分为两组各29例,研究组给予米氮平30mg/d,对照组给予氯丙咪嗪50～150mg/d,疗程6周.采用汉密顿抑郁量表HAMD、汉密顿焦虑量表HAMA,副反应量TESS评定疗效和不良反应.结果研究组显效率为75.9%,对照组为72.4%,两组之间无显著性差异(P>0.05).研究组抗抑郁作用起效较快,不良反应发生率低于对照组,差异显著(P<0.05～0.01).结论米氮平有良好的抗抑郁作用,疗效与氯丙咪嗪相当,起效较快,不良反应轻,安全性高.

Objective To explore the effects and safety of mirtazapine for depression. Methods 58 patients of depression （CCMD-3） were randmly divided into two groups. Patients in study group were treated with mirtazapine 30mg/d for 6 weeks. Patients in control group were treated with Chlorimipramine 50- 150mg/d for 6 weeks. Hamilton Rating Scale for Depression （HAMD）, Hamilton Rating Scale for Anxiety （HAMA） and TESS were done for both groups. Results Effective rate was 75.9% in study group and 72.4% in control group. There was no difference between two groups （P〉0.05）. Therapeutical effects in study group were fast and with lower side effect rates. Conclusion Mirtazapine was satisfactory drugs as ant-depressant, just like Chlorimipramine with lower side effects and safety.